Product
Liso-cel
Aliases
BREYANZI, Lisocabtagene Maraleucel
2 clinical trials
1 drug
7 indications
Indication
Follicular LymphomaIndication
Diffuse Large B Cell LymphomaIndication
High-grade B-cell lymphomaIndication
Mediastinal Large B-cell LymphomaIndication
Indolent B-Cell Non-Hodgkin LymphomaIndication
Non-Hodgkin LymphomaIndication
Refractory Non-Hodgkin LymphomaClinical trial
A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of Lisocabtagene Maraleucel (JCAR017/BMS-986387) to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (TRANSFORM FL)Status: Not yet recruiting, Estimated PCD: 2031-10-16
Clinical trial
Feasibility of Low Dose Radiation as Bridging Therapy for Lisocabtagene Maraleucel in Relapsed B-Cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2025-07-01